Please use this identifier to cite or link to this item: https://hdl.handle.net/10356/148764
Full metadata record
DC FieldValueLanguage
dc.contributor.authorChauffour, Aurélieen_US
dc.contributor.authorRobert, Jérômeen_US
dc.contributor.authorVeziris, Nicolasen_US
dc.contributor.authorAubry, Alexandraen_US
dc.contributor.authorPethe, Kevinen_US
dc.contributor.authorJarlier, Vincenten_US
dc.date.accessioned2021-05-17T08:39:55Z-
dc.date.available2021-05-17T08:39:55Z-
dc.date.issued2020-
dc.identifier.citationChauffour, A., Robert, J., Veziris, N., Aubry, A., Pethe, K. & Jarlier, V. (2020). Telacebec (Q203)-containing intermittent oral regimens sterilized mice infected with Mycobacterium ulcerans after only 16 doses. PLoS Neglected Tropical Diseases, 14(8). https://dx.doi.org/10.1371/journal.pntd.0007857en_US
dc.identifier.issn1935-2727en_US
dc.identifier.urihttps://hdl.handle.net/10356/148764-
dc.description.abstractBuruli ulcer (BU), caused by Mycobacterium ulcerans, is currently treated with a daily combination of rifampin and either injectable streptomycin or oral clarithromycin. An intermittent oral regimen would facilitate treatment supervision. We first evaluated the bactericidal activity of newer antimicrobials against M. ulcerans using a BU animal model. The imidazopyridine amine telacebec (Q203) exhibited high bactericidal activity whereas tedizolid (an oxazolidinone closely related to linezolid), selamectin and ivermectin (two avermectine compounds) and the benzothiazinone PBTZ169 were not active. Consequently, telacebec was evaluated for its bactericidal and sterilizing activities in combined intermittent regimens. Telacebec given twice a week in combination with a long-half-life compound, either rifapentine or bedaquiline, sterilized mouse footpads in 8 weeks, i.e. after a total of only 16 doses, and prevented relapse during a period of 20 weeks after the end of treatment. These results are very promising for future intermittent oral regimens which would greatly simplify BU treatment in the field.en_US
dc.language.isoenen_US
dc.relation.ispartofPLoS Neglected Tropical Diseasesen_US
dc.rights© 2020 Chauffour et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.en_US
dc.subjectScience::Medicineen_US
dc.titleTelacebec (Q203)-containing intermittent oral regimens sterilized mice infected with Mycobacterium ulcerans after only 16 dosesen_US
dc.typeJournal Articleen
dc.contributor.schoolLee Kong Chian School of Medicine (LKCMedicine)en_US
dc.contributor.schoolSchool of Biological Sciencesen_US
dc.identifier.doi10.1371/journal.pntd.0007857-
dc.description.versionPublished versionen_US
dc.identifier.pmid32866170-
dc.identifier.scopus2-s2.0-85090520826-
dc.identifier.issue8en_US
dc.identifier.volume14en_US
dc.subject.keywordsBedaquilineen_US
dc.subject.keywordsImidazole Derivativeen_US
item.fulltextWith Fulltext-
item.grantfulltextopen-
Appears in Collections:LKCMedicine Journal Articles
Files in This Item:
File Description SizeFormat 
pntd.0007857.pdf1.16 MBAdobe PDFThumbnail
View/Open

SCOPUSTM   
Citations 20

10
Updated on Mar 25, 2024

Web of ScienceTM
Citations 20

7
Updated on Oct 31, 2023

Page view(s)

223
Updated on Mar 28, 2024

Download(s) 50

51
Updated on Mar 28, 2024

Google ScholarTM

Check

Altmetric


Plumx

Items in DR-NTU are protected by copyright, with all rights reserved, unless otherwise indicated.